28.8 C
New York
Sunday, June 14, 2026

Tag: e-mail

newssourceFORcompanyinformationcontent1marketreleases

Cobre del Mayo, S.A. de C.V. Announces Exchange Offer

MEXICO CITY, July 22, 2025 /PRNewswire/ -- Cobre del Mayo, S.A. de C.V. ("CDM") announced today that it has commenced an offer (the "Exchange...

Cobre del Mayo, S.A. de C.V. Announces Exchange Offer

MEXICO CITY, July 22, 2025 /PRNewswire/ -- Cobre del Mayo, S.A. de C.V. ("CDM") announced today that it has commenced an offer (the "Exchange...

Cobre del Mayo, S.A. de C.V. Announces Exchange Offer

MEXICO CITY, July 22, 2025 /PRNewswire/ -- Cobre del Mayo, S.A. de C.V. ("CDM") announced today that it has commenced an offer (the "Exchange...

Roche’s Board of Directors proposes exchange of Genussscheine for participation certificates (Partizipationsscheine)

Basel, 22 July 2025 - Roche (SIX: RO, ROG; OTCQX: RHHBY) announced today its Board of Directors' decision to propose to shareholders a modernisation of Roche Holding Ltd’s capital structure for approval at the Annual General Meeting to be held on 10 March 2026 ("2026 AGM"). The proposal includes the exchange of the existing non-voting equity securities (“Genussscheine”) for participation certificates with a nominal value of CHF 0.001 each.

TCL Electronics (01070.HK) Publishes Positive Profit Announcement

Expects Adjusted Profit attributable to Owners of the Parent for 1H 2025 to Grow by Approximately 45% to 65% YoY HONG KONG, July 22, 2025...

uniQure to Announce Second Quarter 2025 Financial Results

uniQure to host earnings call on Tuesday, July 29, 2025 at 8:30 a.m. ET 
uniQure to host earnings call on Tuesday, July 29, 2025 at 8:30 a.m. ET

CONDITIONS FOR SALE OF RIKSBANK CERTIFICATES

Stockholm, 2025-07-22

Strong operational performance, but lower prices – refocused strategy for continued profitable growth

(Oslo, Norway, 22 July 2025) – Statkraft delivered strong operational performance in the second quarter of 2025, despite lower prices, especially in the northern price areas of Norway and Sweden. Net results were negatively impacted by impairments, mostly due to lower estimated future power prices in certain regions, and currency effects. Statkraft continues to refocus for profitable growth.

Gainey McKenna & Egleston Announces A Class Action Lawsuit Has Been Filed Against Neogen Corporation (NEOG)

NEW YORK, July 21, 2025 (GLOBE NEWSWIRE) -- Gainey McKenna & Egleston announces that a securities class action lawsuit has been filed in the United States District Court for the Western District of Michigan on behalf of all persons or entities who purchased or otherwise acquired Neogen Corporation (“Neogen” or the “Company”) (NASDAQ: NEOG) securities between January 5, 2023 and June 3, 2025, both dates inclusive (the “Class Period”).

Notice on the General Meeting of Shareholders of the AUGA group, AB entity under restructuring on 12 August 2025 to approve the Company’s draft...

AUGA group, AB entity under restructuring (code 126264360, registered office at Konstitucijos pr. 21C, Vilnius, hereinafter referred to as the “Company”), by the initiative and decision of the Board, is convening a General meeting of shareholders on August 12, 2025, at 10:00 a.m., where the Company’s shareholders will vote on the approval of the Company’s draft restructuring plan, hereinafter referred to as the “Meeting”.

Share buy-back program

COMPANY ANNOUNCEMENT NO 38/2025 - JULY 21, 2025

Heineken N.V. reports the progress of transactions under its current share buyback programme

Heineken N.V. reports the progress of transactions under its current
 share buyback programme

The Ether Machine to Go Public with Over $1.5 Billion of Fully Committed Capital

The Ether Machine expected to launch with over 400,000 Ether ("ETH") and manage the largest pool of assets in a public vehicle for pure-play...

[Ad hoc announcement pursuant to Art. 53 LR] Roche provides update on astegolimab in chronic obstructive pulmonary disease

Basel, 21 July 2025 - Roche (SIX: RO, ROG; OTCQX: RHHBY) announced today topline results from the pivotal phase IIb ALIENTO (n=1,301) and the phase III ARNASA (n=1,375) trials investigating astegolimab compared to placebo, on top of standard of care maintenance therapy in people with moderate to very severe chronic obstructive pulmonary disease (COPD). The studies included a broad population: both former and current smokers, regardless of blood eosinophil count, who have a history of frequent exacerbations.

- A word from our sponsors -

spot_img

Newsletter Signup

Name(Required)
Email(Required)
Privacy(Required)
This field is for validation purposes and should be left unchanged.
HomeTagsE-mail

Explore

Press Releases

News & Opinion

Living

Others

Follow us

© Copyright 2025. BusinessPressWire® / 14 Wall Street New York City NY 10005 +1 888-502-0266 / Disclaimers